Minerva Neurosciences Stock Today
| NERV Stock | USD 1.80 0.07 4.05% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Minerva Neurosciences is selling for under 1.80 as of the 22nd of March 2025; that is 4.05 percent increase since the beginning of the trading day. The stock's lowest day price was 1.72. Minerva Neurosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of July 2014 | Category Healthcare | Classification Health Care |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. The company has 6.99 M outstanding shares of which 42.04 K shares are now shorted by private and institutional investors with about 1.16 trading days to cover. More on Minerva Neurosciences
Moving together with Minerva Stock
Moving against Minerva Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Minerva Stock Highlights
| President | MBA FCMA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMinerva Neurosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Minerva Neurosciences' financial leverage. It provides some insight into what part of Minerva Neurosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minerva Neurosciences (NERV) is traded on NASDAQ Exchange in USA. It is located in 1500 District Avenue, Burlington, MA, United States, 01803 and employs 8 people. Minerva Neurosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.1 M. Minerva Neurosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.99 M outstanding shares of which 42.04 K shares are now shorted by private and institutional investors with about 1.16 trading days to cover.
Minerva Neurosciences currently holds about 40.22 M in cash with (19.55 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Minerva Neurosciences Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Minerva Neurosciences is $12.1 Million. Minerva Neurosciences holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Check Minerva Ownership Details
Minerva Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Royal Bank Of Canada | 2024-12-31 | 1.5 K | |
| Tower Research Capital Llc | 2024-12-31 | 1.4 K | |
| Tfc Financial Management | 2024-12-31 | 186 | |
| Northwestern Mutual Wealth Management Co | 2024-12-31 | 100.0 | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 62.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 53.0 | |
| Bank Of America Corp | 2024-12-31 | 45.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 17.0 | |
| Ubs Group Ag | 2024-12-31 | 12.0 | |
| Federated Hermes Inc | 2024-12-31 | 1.4 M | |
| Vanguard Group Inc | 2024-12-31 | 252.1 K |
Minerva Neurosciences Historical Income Statement
Minerva Stock Against Markets
Minerva Neurosciences Corporate Management
| CPA CPA | CFO VP | Profile | |
| Ramana Kuchibhatla | Senior Development | Profile | |
| FCMA FCMA | President | Profile | |
| William Boni | Vice Communications | Profile |
Additional Tools for Minerva Stock Analysis
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.